SASaeed Khaled Alzghari

Saeed Khaled Alzghari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saeed Khaled Alzghari has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • BRAF inhibitor exposure during pregnancy: A systematic review

    by Kristina C. Hermanson, Casey L. Keller, Ryan M. Schuller, Aasmitha Mistry, Saeed K. Alzghari

    Objective: BRAF inhibitors have been integrated into the treatment of several malignancies targeting the BRAF V600E-variant. However, there is limited evidence of the use of BRAF inhibitors in pregnancy. Hence, the purpose of this systematic review is to synthesize published reports evaluating the risk-benefit of BRAF inhibitor exposure during pregnancy. Methods: A systematic search was conducted of PubMed, Scopus, Embase, Web of Science, and CINAHL Ultimate for articles published between January 1, 1966 and June 15, 2026. Included studies were those that involved women with a cancer diagnosis who received a BRAF inhibitor while pregnant and had clinical findings of the fetus post-BRAF inhibitor treatment. Results: In total, 422 records were screened, yielding 7 cases of BRAF-inhibitor exposure during pregnancy. All patients presented with melanoma and vemurafenib was given in all but one case that used dabrafenib. Age of the mothers ranged from 25–37 years old. BRAF-inhibitor exposure occurred during the second trimester in 5 cases and in 1 case during the third trimester. Gestational age at delivery ranged from 26–36 weeks. The mother was alive at presentation in 2 of the 5 reported cases. Fetal adverse events occurred in 4 of the 7 cases including paroxysmal supraventricular tachycardia, intrauterine growth restriction, heart malformations, and delayed cranial ossification. Conclusion: In this systematic review, BRAF inhibitor therapy during the second or third trimester of pregnancy may be associated with viable outcomes but carry significant potential risks to the fetus. Clinicians should approach BRAF inhibitor use during pregnancy with individualized, multi-disciplinary discussions.

  • Immune Checkpoint Inhibitor Exposure During Pregnancy: A Systematic Review

    by Casey L. Keller, Kristina C. Hermanson, Ryan M. Schuller, Saeed K. Alzghari

    Immune checkpoint inhibitors (ICIs) have been widely implemented in current oncology practice. However, there is limited data regarding ICI administration in pregnancy. This systematic review aims to evaluate the risk–benefit of ICI exposure in pregnant women. We conducted searches in databases including PubMed, Scopus, Web of Science, and Embase from January 1, 2011 through April 30, 2025. Included studies were those that involved women with a cancer diagnosis who received ICI treatment while pregnant and had clinical findings of the fetus post‐ICI treatment. Methodological quality and potential sources of bias were assessed using Joanna Briggs Institute Critical Appraisal Tools. The search generated 2539 citations. After removal of 696 duplicates, a total of 1843 citations were screened. Twenty case reports and three retrospective studies were included in the systematic review. Fetal complications and fetal immune‐related adverse events among the case reports were at 23% and 11.5%, respectively. Preterm delivery occurred in 54% of case reports, and no fetal mortalities were reported. Regarding the observational studies, preterm delivery occurred in 20.9%–25.5% of cases, fetal mortality occurred in 2.2%–15.3% of cases, intrauterine growth restriction occurred in 6.5%–7.1% of cases, and complications attributable to prematurity were reported in 2.6%–5.5% of cases. The data from this systematic review suggests that the risk for fetal complications may be lower than previously reported. As ICIs continue to expand their role in the treatment of malignancy, their use in pregnancy is more likely to come into clinical question. Clinicians should approach ICI use in pregnancy with individualized, multi‐disciplinary risk–benefit discussions.


  • Subcutaneous immune checkpoint inhibitors: A new era in oncology care

    by Casey L. Keller, Ryan M. Schuller, Saeed K. Alzghari

  • Open Access

    Treating Non-fentanyl-derived Synthetic Opioid Overdose with a Traditional Opioid Reversal Agent

    by Valerie S. Acuna, Ethan M. Abels, Amir Alhelwani, Saeed K. Alzghari

    As the opioid crisis in the United States continues to grow, non-fentanyl-derived synthetic opioids (NSOs) are growing in both availability and popularity. NSO use comes with considerable risk including a high potential for both abuse and overdose. In this editorial, we review the consequences of overdose with the NSOs U-47700 and butyrfentanyl (BF) and the potential for the use of naloxone as a treatment for such instances. Naloxone administration was found successful in reversing opioid effects and re-establishing independent breathing in a patient taking U-47700 or BF. With a high rate of success in treating opioid overdose and a low chance of negatively affecting healthy non-dependent persons, naloxone is an ideal medication in these situations. We recommend the use of naloxone in cases of NSO opioid overdose and advocate for the increased availability of naloxone products to improve overdose outcomes nationwide.


  • Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer

    by Ninh M. La‐Beck, Dung T. Nguyen, Alex D. Le, Saeed K. Alzghari, Saralinh T. Trinh

    The rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) now includes two agents, pembrolizumab and atezolizumab, approved for first‐line treatment of advanced non–small cell lung cancer (aNSCLC) as monotherapy or as part of chemoimmunotherapy. This review summarizes the clinical evidence supporting these indications, with a focus on strategies to optimize patient outcomes. These strategies include patient and tumor factors, adverse‐effect profiles, pharmacokinetic and pharmacodynamic drug interactions, and quality of life and cost‐effectiveness considerations. We performed a systematic literature search of the PubMed, Scopus, and Google Scholar databases, as well as a search of the conference proceedings of the American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research (through August 31, 2019). The addition of ICIs to conventional chemotherapy as first‐line treatment against aNSCLC is now part of the standard of care options. However, even though ICIs may be cost‐effective in patients with aNSCLC, high drug and other associated costs can still be a barrier to treatment for patients. Moreover, the adverse‐effect profiles of ICIs differ significantly from conventional chemotherapy, and some immune‐related adverse effects may have a lasting impact on quality of life. Therefore, in adhering to a patient‐centered model of care, clinicians should be mindful of patient‐ and treatment‐specific factors when considering therapeutic options for patients with aNSCLC. Although the role of the immune system in cancer progression and regression has not been fully elucidated, the full clinical potential of immunotherapeutics in the treatment of cancer likely remains to be unleashed.


  • Open Access

    The Road to a Hypoglycemic Care Model

    by Markus Moore, Saeed K. Alzghari

    Hypoglycemia is a modifiable condition that causes mortality and readmission rates to increase in a hospital setting. The condition is worsened by its complications, quick onset, and an absence of a protocol mapped out by hospitals. This complication does not come from one origin, but rather from a range of barriers. Research from a variety of sources, such as those found from the American Diabetes Association, have shown great promises in ways to treat and prevent hypoglycemia that are of importance to highlight for practitioners in the inpatient setting.

  • Open Access

    Systematic review of the clinical consequences of butyrfentanyl and corresponding analogues

    by Alexander Dinh Le, Saeed Khaled Alzghari

    Butyrfentanyl and its analogues are being increasingly used throughout the United States and Europe. Currently, lethal cases are emerging across the United States, England, and Europe without any end in sight. We therefore performed a systematic review of existing case reports on the literature of butyrfentanyl and similar analogs. We searched PubMed and Embase for articles (up until September 2018) using terms such as “butyrfentanyl” or “butyrylfentanyl.” In total, our search found 271 articles and identified 10 for inclusion in this review. A total of 33 cases were found with 61% of those being fatal. The most common route of administration was intravenous, but other routes of administration were readily used such as oral, intranasal, and inhalation. Most cases reported use of concomitant licit and illicit pharmacological agents. The toxidrome was consistent with other opioid overdoses, and naloxone was successfully used in nine of 10 patients. We encourage toxicology screenings of novel fentanyl analogs such as butyrfentanyl or 4-fluorobutyrfentanyl when an opioid overdose of unknown nature presents.


  • Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango

    by Stefania Koutsilieri, Kelly E. Caudle, Saeed Khaled Alzghari, Andrew A. Monte, Mary V. Relling, George P. Patrinos


  • Open Access

    The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety

    by Nathan R. Ching, Amna K. Alzghari, Saeed K. Alzghari

    Anxiety affects over 260 million people worldwide. Benzodiazepines are a class of agents used in combination with other therapies for the management of anxiety. Lorazepam is a commonly prescribed benzodiazepine metabolized by uridine 5'-diphosphate-glucuronosyltransferases. Herein, we discuss recent findings regarding the pharmacogenetics of uridine 5'-diphosphate-glucuronosyltransferase 2B15 (UGT2B15), lorazepam, and its role in the treatment of anxiety.